Seagen Inc.
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
- Conditions
- Disease, Hodgkin
- Interventions
- First Posted Date
- 2010-02-02
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT01060904
- Locations
- πΊπΈ
Mayo Clinic, Rochester, Minnesota, United States
πΊπΈUNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States
πΊπΈMD Anderson Cancer Center / University of Texas, Houston, Texas, United States
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
- Conditions
- Lymphoma, Large-Cell, AnaplasticDisease, HodgkinNeoplasmsCarcinomasLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT01026415
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
πΊπΈColorado Blood Cancer Institute, Denver, Colorado, United States
πΊπΈSt. Francis Medical Group Oncology & Hematology Specialists, Indianapolis, Indiana, United States
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
- Conditions
- Lymphoma, Large-Cell, AnaplasticLymphoma, Non-HodgkinDisease, Hodgkin
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01026233
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈCity of Hope National Medical Center, Duarte, California, United States
πΊπΈStanford Cancer Center, Stanford, California, United States
A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT01015911
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈCity of Hope National Medical Center, Duarte, California, United States
πΊπΈUCLA Medical Center / University of California at Los Angeles, Los Angeles, California, United States
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
- Conditions
- Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT00947856
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈCity of Hope National Medical Center, Duarte, California, United States
πΊπΈStanford Cancer Center, Stanford, California, United States
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
- Conditions
- Lymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT00866047
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈStanford University Medical Center, Palo Alto, California, United States
πΊπΈRocky Mountain Cancer Centers, Denver, Colorado, United States
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT00848926
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈCity of Hope National Medical Center, Duarte, California, United States
πΊπΈUniversity of California at Los Angeles, Los Angeles, California, United States
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
- Conditions
- Lymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00655837
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈMayo Clinic Arizona, Scottsdale, Arizona, United States
πΊπΈUniversity of Colorado, Aurora, Colorado, United States
A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
- Conditions
- Cancer
- Interventions
- Drug: ARRY-380, HER2 inhibitor; oral
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00650572
- Locations
- πΊπΈ
The University of Colorado Cancer Center, Aurora, Colorado, United States
πΊπΈThe University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
π¨π¦British Columbia Cancer Agency, Vancouver, British Columbia, Canada
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
- Conditions
- Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00649584
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈStanford University Medical Center, Palo Alto, California, United States
πΊπΈUniversity of Miami, Miami, Florida, United States